Resistance of collagenase-2 (matrix metalloproteinase-8)-deficient mice to TNF-induced lethal hepatitis

Journal of Immunology

Volumn 175, Issue 11, 2005, Pages 7642-7649

  Van Lint, Philippe ^a   Wielockx, Ben ^a,d   Puimège, Leen ^a   Noël, Agnès ^b   López Otin, Carlos ^c   Libert, Claude ^a  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CHEMOKINE; COLLAGENASE 2; MATRIX METALLOPROTEINASE INHIBITOR; NEUTROPHIL COLLAGENASE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; HEPATITIS; INTENSIVE CARE; LIVER FAILURE; LIVER NECROSIS; LIVER PROTECTION; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL;

EID: 28244445602     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.175.11.7642     Document Type: Article

References (32)

1. Schiodt, F. V., and W. M. Lee. 2003. Fulminant liver disease. Clin. Liver Dis. 7: 331-349.
2. Lee, W. M. 1993. Acute liver failure. N. Engl. J. Med. 329: 1862-1872.
3. Muto, Y., K. T. Nouri-Aria, A. Meager, G. J. Alexander, A. L. Eddleston, and R. Williams. 1988. Enhanced tumour necrosis factor and interleukin-1 in fulminant hepatic failure. Lancet 2: 72-74.
4. Fransen, L., M. R. Ruysschaert, J. Van der Heyden, and W. Fiers. 1986. Recombinant tumor necrosis factor: species specificity for a variety of human and murine transformed cell lines. Cell. Immunol. 100: 260-267.
5. Brouckaert, P. G., G. G. Leroux-Roels, Y. Guisez, J. Tavernier, and W. Fiers. 1986. in vivo anti-tumour activity of recombinant human and murine TNF, alone and in combination with murine IFN-γ, on a syngeneic murine melanoma. Int. J. Cancer 38: 763-769.
6. Eggermont, A. M. 1998. TNFα in isolated perfusion systems: success in the limb, developments for the liver credits, debits and future perspectives. Anticancer Res. 18: 3899-3905.
7. Tracey, K. J., B. Beutler, S. F. Lowry, J. Merryweather, S. Wolpe, I. W. Milsark, R. J. Hariri, T. J. Fahey III, A. Zentella, and J. D. Albert. 1986. Shock and tissue injury induced by recombinant human cachectin. Science 234: 470-474.
8. Knittel, T., M. Mehde, D. Kobold, B. Saile, C. Dinter, and G. Ramadori. 1999. Expression patterns of matrix metalloproteinases and their inhibitors in parenchymal and non-parenchymal cells of rat liver: regulation by TNF-α and TGF-β1. J. Hepatol. 30: 48-60.
9. McCawley, L. J., and L. M. Matrisian. 2001. Matrix metalloproteinases: they're not just for matrix anymore! Curr. Opin. Cell Biol. 13: 534-540.
10. Wielockx, B., K. Lannoy, S. D. Shapiro, T. Itoh, S. Itohara, J. Vandekerckhove, and C. Libert. 2001. Inhibition of matrix metalloproteinases blocks lethal hepatitis and apoptosis induced by tumor necrosis factor and allows safe antitumor therapy. Nat. Med. 7: 1202-1208.
11. Balbin, M., A. Fueyo, A. M. Tester, A. M. Pendas, A. S. Pitiot, A. Astudillo, C. M. Overall, S. D. Shapiro, and C. Lopez-Otin. 2003. Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat. Genet. 35: 252-257.
12. Van den Steen, P. E., S. J. Husson, P. Proost, J. Van Damme, and G. Opdenakker. 2003. Carboxyterminal cleavage of the chemokines MIG and IP-10 by gelatinase B and neutrophil collagenase. Biochem. Biophys. Res. Commun. 310: 889-896.
13. Van Den Steen, P. E., A. Wuyts, S. J. Husson, P. Proost, J. Van Damme, and G. Opdenakker. 2003. Gelatinase B/MMP-9 and neutrophil collagenase/MMP-8 process the chemokines human GCP-2/CXCL6, ENA-78/CXCL5 and mouse GCP-2/LIX and modulate their physiological activities. Eur. J. Biochem. 270: 3739-3749.
14. Decker, K., and D. Keppler. 1974. Galactosamtne hepatitis: key role of the nucleotide deficiency period in the pathogenesis of cell injury and cell death. Rev. Physiol. Biochem. Pharmacol. 71: 77-106.
15. Van Molle, W., G. Denecker, I. Rodriguez, P. Brouckaert, P. Vandenabeele, and C. Libert. 1999. Activation of caspases in lethal experimental hepatitis and prevention by acute phase proteins. J. Immunol. 163: 5235-5241.
16. Gujral, J. S., A. Farhood, and H. Jaeschke. 2003. Oncotic necrosis and caspase-dependent apoptosis during galactosamine-induced liver injury in rats. Toxicol. Appl. Pharmacol. 190: 37-46.
17. Jaeschke, H., Y. S. Ho, M. A. Fisher, J. A. Lawson, and A. Farhood. 1999. Glutathione peroxidase-deficient mice are more susceptible to neutrophil-mediated hepatic parenchymal cell injury during endotoxemia: importance of an intracellular oxidant stress. Hepatology 29: 443-450.
18. Patel, D. D., W. Koopmann, T. Imai, L. P. Whichard, O. Yoshie, and M. S. Krangel. 2001. Chemokines have diverse abilities to form solid phase gradients. Clin. Immunol. 99: 43-52.
19. Rot, A., and U. H. von Andrian. 2004. Chemokines in innate and adaptive host defense: basic chemokinase grammar for immune cells. Annu. Rev. Immunol. 22: 891-928.
20. Wuyts, A., A. D'Haese, V. Cremers, P. Menten, J. P. Lenaerts, A. De Loof, H. Heremans, P. Proost, and J. Van Damme. 1999. NH2- and COOH-terminal truncations of murine granulocyte chemotactic protein-2 augment the in vitro and in vivo neutrophil chemotactic potency. J. Immunol. 163: 6155-6163.
21. Silverstein, R. 2004. D-galactosamine lethality model: scope and limitations. J. Endotoxin Res. 10: 147-162.
22. Jaeschke, H., A. Farhood, and C. W. Smith. 1991. Neutrophil-induced liver cell injury in endotoxin shock is a CD11b/CD18-dependent mechanism. Am. J. Physiol. 261: 1051-1056.
23. Devarajan, P., K. Mookhtiar, H. Van Wart, and N. Berliner. 1991. Structure and expression of the cDNA encoding human neutrophil collagenase. Blood 77: 2731-2738.
24. Hanemaaijer, R., T. Sorsa, Y. T. Konttinen, Y. Ding, M. Sutinen, H. Visser, V. W. van Hinsbergh, T. Helaakoski, T. Kainulainen, H. Ronka, et al. 1997. Matrix metalloproteinase-8 is expressed in rheumatoid synovial fibroblasts and endothelial cells: regulation by tumor necrosis factor-α and doxycycline. J. Biol. Chem. 272: 31504-31509.
25. Smith, J. B., L. E. Rovai, and H. R. Herschman. 1997. Sequence similarities of a subgroup of CXC Chemokines related to murine LIX: implications for the interpretation of evolutionary relationships among chemokines. J. Leukocyte Biol. 62: 598-603.
26. Lortat-Jacob, H., A. Grosdidier, and A. Imberty. 2002. Structural diversity of heparan sulfate binding domains in chemokines. Proc. Natl. Acad. Sci. USA 99: 1229-1234.
27. Jung, U., K. E. Norman, K. Scharffetter-Kochanek, A. L. Beaudet, and K. Ley. 1998. Transit time of leukocytes rolling through venules controls cytokine-induced inflammatory cell recruitment in vivo. J. Clin. Invest. 102: 1526-1533.
28. Sternlicht, M. D., and Z. Werb. 2001. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell. Dev. Biol. 17: 463-516.
29. Chosay, J. G., N. A. Essani, C. J. Dunn, and H. Jaeschke. 1997. Neutrophil margination and extravasation in sinusoids and venules of liver during endotoxin-induced injury. Am. J. Physiol. 272: 1195-1200.
30. Bahjat, F. R., V. R. Dharnidharka, K. Fukuzuka, L. Morel, J. M. Crawford, M. J. Clare-Salzler, and L. L. Moldawer. 2000. Reduced susceptibility of nonobese diabetic mice to TNF-α and D-galactosamine-mediated hepatocellular apoptosis and lethality. J. Immunol. 165: 6559-6567.
31. Key, N. S., J. L. Platt, and G. M. Vercellotti. 1992. Vascular endothelial cell proteoglycans are susceptible to cleavage by neutrophils. Arterioscler. Thromb. 12: 836-842.
32. Li, X., D. Klintman, Q. Liu, T. Sato, B. Jeppsson, and H. Thorlacius. 2004. Critical role of CXC chemokines in endotoxemic liver injury in mice. J. Leukocyte Biol. 75: 443-452.